Related Experiment Videos
NK-cell neoplasms in Japan.
Kazuo Oshimi1, Keisei Kawa, Shigeo Nakamura
1Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan. oshimi@med.juntendo.ac.jp
Hematology (Amsterdam, Netherlands)
|July 16, 2005
Summary
This study clarifies rare natural killer (NK) cell neoplasms, revealing distinct clinical features and prognoses for subtypes like nasal NK-cell lymphoma and aggressive NK-cell leukemia. Survival varied significantly among these rare cancers.
Area of Science:
- Hematology
- Oncology
- Immunology
Background:
- Natural killer (NK) cell neoplasms are rare, with poorly understood clinical characteristics.
- Accurate diagnosis and classification are crucial for effective treatment strategies.
Purpose of the Study:
- To elucidate the clinical features and outcomes of rare neoplasms originating from precursor and mature natural killer (NK) cells.
- To analyze data from a nationwide survey of NK cell-lineage neoplasms diagnosed in Japan between 1994 and 1998.
Main Methods:
- A nationwide survey in Japan collected data on 237 patients with putative NK cell-lineage neoplasms.
- Analysis included classification into subtypes: myeloid/NK-cell precursor acute leukemia, blastic NK-cell lymphoma, precursor NK-cell acute lymphoblastic leukemia, aggressive NK-cell leukemia/lymphoma, nasal-type NK-cell lymphoma, and chronic NK lymphocytosis.
Main Results:
- Survival times varied widely, from 2 months for aggressive NK-cell leukemia/lymphoma to over 8 years for chronic NK lymphocytosis.
- Nasal and extranasal NK-cell lymphomas shared histology but differed in sex predilection and disease stage.
- Epstein-Barr virus was detected in all tested nasal NK-cell lymphoma cases, suggesting a causative role.
Conclusions:
- NK cell-lineage neoplasms exhibit diverse clinical presentations and prognoses.
- Nasal NK-cell lymphoma is strongly associated with Epstein-Barr virus.
- Further research is needed to differentiate aggressive NK-cell leukemia/lymphoma and extranasal NK-cell lymphoma.